Head to head
Semaglutide against Metformin
The drug most people are given first and the drug most people ask about. They are not interchangeable: one is an oral generic with decades of use and a consistently null geroscience record, the other a GLP-1 agonist with large weight and cardiovascular trials. The overlap is type 2 diabetes, and the divergence is everything else.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
MetforminMetformin hydrochloride (biguanide)
The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Side by side, on the facts we can check
| Attribute | Semaglutide | Metformin |
|---|---|---|
| Category | Metabolic | Longevity |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. |
| Half-life | ~7 days | 4 to 9 hours (plasma), longer in erythrocytes |
| Molecular weight | 4,113.6 Da | 129.2 Da (165.6 Da as hydrochloride) |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Inhibits mitochondrial complex I and activates AMPK, reducing hepatic glucose output and improving insulin sensitivity. The AMPK account is incomplete and the relative contribution of complex I inhibition, mitochondrial glycerophosphate dehydrogenase and gut-mediated effects is actively disputed between research groups. |
| Human studies cited | 5 | 3 |
| Legal status, US | FDA-approved, prescription only | Prescription only; approved for type 2 diabetes |
Frequently asked questions
What is the difference between Semaglutide and Metformin?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Metformin: The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Which has stronger research evidence, Semaglutide or Metformin?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 3 of 4 for Metformin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Metformin FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity..
Related posts
Blog articles that cover Semaglutide or Metformin, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.